Evidence map›Paper›PMID 30112652›Full record

ReviewCurrent diabetes reports2018

Inpatient Glycemic Management in the Setting of Renal Insufficiency/Failure/Dialysis.

Ravi Iyengar, Jennifer Franzese, Roma Gianchandani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Management of diabetes and hyperglycaemia in the hospital.The lancet. Diabetes & endocrinology · 2021 · on this map
    Review
  8. Basal-Bolus Insulin Regimen for Hospitalised Patients with COVID-19 and Diabetes Mellitus: A Practical Approach.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ravi IyengarDepartment of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Domino's Farms (Lobby G, Suite 1500) 24 Frank Lloyd Wright Drive, Ann Arbor, MI, 48106, USA.
Jennifer FranzeseDepartment of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Domino's Farms (Lobby G, Suite 1500) 24 Frank Lloyd Wright Drive, Ann Arbor, MI, 48106, USA.
Roma GianchandaniDepartment of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Domino's Farms (Lobby G, Suite 1500) 24 Frank Lloyd Wright Drive, Ann Arbor, MI, 48106, USA. romag@med.umich.edu.
University of Michigan–Ann Arbor · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of this reviewChronic diabetic nephropathy and renal dysfunction from other causes are common in hospitalized patients with diabetes. Available diabetes management guidelines aim to reduce hyperglycemia and hypoglycemia, both independent risk factors for hospital outcomes. Renal dysfunction, which increases the risk of hypoglycemia, adds a layer of complexity in diabetes management. Therefore, modified glucose goals and treatment regimens may be required. RECENT

findingsRecent prospective and retrospective studies provide direction on safe insulin therapy for diabetes inpatients with renal compromise. Studies of newer diabetes pharmacotherapy provide data on oral agent use in the inpatient setting. Diabetes therapy should be modified with changing renal function. Glucose management in patients on peritoneal or hemodialysis is challenging. Reducing weight-based doses of insulin and use of newer insulins can reduce hypoglycemia risk. Safety and efficacy of DPP-4 inhibitors has been evaluated in the hospital and nursing home setting. Metformin, SGLT-2 inhibitors, and GLP1 receptor agonists can be used in several stages of renal dysfunction prior to and at discharge.

Indexed as

InpatientsRenal DialysisDiabetes MellitusHumansHyperglycemiaHypoglycemic AgentsRenal InsufficiencyHypoglycemic AgentsAntidiabetic agentsEnd-stage renal diseaseHemodialysisInpatient diabetesInsulin managementPeritoneal Dialysis

Identifiers

PMID30112652
OpenAlexW2885841774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.